Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Mineur

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 28, 2012
Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithmZ Reguiai, J B Bachet, C Bachmeyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 23, 2015
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trialM Hebbar, B Chibaudel, T André, et al.
Plos One|December 21, 2020
PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancerL Mineur, E François, C Plassot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancerD Azria, J Doyen, M Jarlier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2014
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trialM Hebbar, B Chibaudel, T André, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 28, 2012
Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithmZ Reguiai, J B Bachet, C Bachmeyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 23, 2015
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trialM Hebbar, B Chibaudel, T André, et al.
Plos One|December 21, 2020
PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancerL Mineur, E François, C Plassot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancerD Azria, J Doyen, M Jarlier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2014
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trialM Hebbar, B Chibaudel, T André, et al.
Pageof 4